Obesity and Alzheimer’s drugs pack one-two punch to power Eli Lilly higher in 2024
[ad_1] Investor optimism for Eli Lilly ‘s diabetes and obesity treatments in 2023 lifted the stock to its seventh annual gain in a row. In the new year, it should … Read More